Skip to main content

Market Overview

NLS Pharmaceutics Stock Surges On Obesity Drug Licensing Pact With Novartis Pharma


NLS Pharmaceutics AG (NASDAQ: NLSP) stock has more than doubled in reaction to a License Agreement with Novartis Pharma AG, a unit of Novartis AG (NYSE: NVS), wherein NLS secured an exclusive license to Sanorex (mazindol) in the U.S.

  • Sandoz developed Sanorex as an immediate-release obesity drug designed to shed pounds fast.
  • The agreement encompasses all preclinical and clinical studies, data used for manufacturing, formulation data, and know-how for all products containing mazindol as an active substance, post-marketing clinical studies, and periodic safety reports.
  • Under the agreement, NLS has obtained the same rights on a non-exclusive basis outside the U.S., except for Japan.
  • The agreement includes the right to sublicense or assign the license to third parties.
  • NLS went public in January this year and priced its IPO at $4.15 per unit.
  • Price Action: NLSP shares have surged 123.4% at $6.29 in market trading hours on the last check Friday.

Related Articles (NVS + NLSP)

View Comments and Join the Discussion!

Posted-In: obesityBiotech News Penny Stocks Health Care Offerings FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at